Introduction: Scientific information on the antidepressant effectiveness of the varied usual therapeutic interventions is considerable but of poor quality. Objective: To analyse the scientifically well qualified international contributions on the effectiveness of habitual psychobiological psychiatric interventions in depressive disorders. Method: N= 6 structured bibliographic systems have been reviewed in a non-systematic, narrative and synthetic way and N= 75 significant contributions have been selected. Results and discussion: Patients with severe depression are more likely to receive any type of medical attention, but less likely to receive adequate attention. The use of both drugs and psychotherapy is the habitual mixed combined intervention during any ordinary psychiatric treatment. We will call it psychobiological or psychopharmacological intervention. The exclusive psychological intervention without using any medically prescribed drugs, is likely to be less cost/effective. The matter is not only to prioritise but also to adequately combine psychiatric interventions and added psychological interventions when convenient. The intervention on the neurophysiological pathways related with glutamate, the GABAergic, opioidergic, and inflammatory systems as well as on connectome and microbiome are being promoted for future drug antidepressant therapy with encouraging results. Conclusion: The mixed psychiatric option using drugs and psychotherapy, either regulated or not, by the intervening psychiatrist himself or herself is probably the main therapeutic choice for the correctly diagnosed depressive disorders. The psychotherapeutics intervention excluding the psychobiological psychiatric intervention in correctly diagnosed depressions will be insufficient in general. The professional psychological intervention may obviously complement the mixed psychiatric intervention, but can not replace it.
| Published in | American Journal of Psychiatry and Neuroscience (Volume 11, Issue 1) |
| DOI | 10.11648/j.ajpn.20231101.12 |
| Page(s) | 13-21 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2023. Published by Science Publishing Group |
Depressive Disorder, Depression, Mini-Review, Psychobiology, Psychopharmacology, Psychotherapy, Treatment of Resistant Depression
| [1] | Leichsenring F, Steinert C, Rabung S, Ioannidis JPA. The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: An umbrella review and meta-analytic evaluation of recent meta-analyses. World Psychiatry 2022; 21 (1): 133–45. doi: 10.1002/wps.20941 |
| [2] | Blais MA, Malone JC, Stein MB, Slavin-Mulford J, O'Keefe SM, Renna M, et al. Treatment as usual (TAU) for depression: A comparison of psychotherapy, pharmacotherapy, and combined treatment at a large academic medical center. Psychotherapy (Chic) 2013; 50 (1): 110–8. doi: 10.1037/a003138 |
| [3] | Howick J, Koletsi D, Loannidis JPA, Madigan C, Pandis N, Loef M, et al. Most healthcare interventions tested in Cochrane Reviews are not effective according to high quality evidence: A systematic review and meta-analysis. Journal of Clinical Epidemiology 2022; 148: 160–9. doi: 10.1016/j.jclinepi.2022.04.017 |
| [4] | Vigo DV, Kazdin AE, Sampson NA, Hwang I, Alonso J, Andrade LH, et al. Determinants of effective treatment coverage for major depressive disorder in the WHO World Mental Health Surveys. International Journal of Mental Health Systems 2022; 16 (1): 29. doi: 10.1186/s13033-022-00539-6 |
| [5] | Henssler J, Bschor T, Baethge C. Combining antidepressants in acute treatment of depression: A meta-analysis of 38 studies including 4511 patients. Canadian Journal of Psychiatry 2016; 61 (1): 29–43. doi: 10.1177/0706743715620411 |
| [6] | Bertolín-Guillén JM. Antipsicóticos atípicos como coadyuvantes en el tratamiento de los trastornos de ansiedad y depresivos. [Atypical antipsychotics as coadjuvants in the treatment of anxiety and depressive disorders.] Psicosomática y Psiquiatría 2023. [article in press]. |
| [7] | Rhee TG, Mohamed S, Rosenheck RA. Antipsychotic prescriptions among adults with major depressive disorder in office-based outpatient settings: National trends from 2006 to 2015. Journal of Clinical Psychiatry 2018; 79 (2): 17m11970. doi: 10.4088/JCP.17m11970 |
| [8] | Cuijpers P, Oud M, Karyotaki E, Noma H, Quero S, Cipriani A, et al. Psychologic treatment of depression compared with pharmacotherapy and combined treatment in primary care: A network meta-analysis. Annals of Family Medicine 2021; 19 (3): 262–70. https://doi.org/10.1370/afm.2676 |
| [9] | Bertolín-Guillén JM. Current state of psychopharmacology, psychotherapies and other interventions in mental health problems and disorders. European Journal of Applied Sciences 2021; 9 (5): 251–61. https://journals.scholarpublishing.org/index.php/AIVP/article/view/10994 |
| [10] | Seifert J, Maier HB, Führmann F, Bleich S, Stübner S, Sieberer M, et al. Pharmacological treatment of major depressive disorder according to severity in psychiatric inpatients: Results from the AMSP pharmacovigilance program from 2001-2017. Journal of Neural Transmission 2022; 129 (7): 925–44. doi: 10.1007/s00702-022-02504-6 |
| [11] | Bandelow B, Werner AM, Kopp I, Rudolf S, Wiltink J, Beutel ME. The German Guidelines for the treatment of anxiety disorders: First revision. European Archives of Psychiatry and Clinical Neuroscience 2022; 272 (4): 571–82. doi: 10.1007/s00406-021-01324-1 |
| [12] | Mármol-Fábrega A, Inchauspe-Aróstegui JA, Valverde-Eizaguirre MA. Hacia una psicofarmacoterapia razonada. [Towards a reasoned psychopharmacotherapy.] Revista de la Asociación Española de Neuropsiquiatría 2018; 38 (133): 171–80. doi: 10.4321/S0211-57352018000100009 |
| [13] | Han C, Wang SM, Bahk WM, Lee SJ, Patkar AA, Masand PS, et al. A pharmacogenomic-based antidepressant treatment for patients with major depressive disorder: Results from an 8-week, randomized, single-blinded clinical trial. Clinical Psychopharmacology and Neuroscience 2018; 16 (4): 469–80. doi: 10.9758/cpn.2018.16.4.469 Erratum in: Clinical Psychopharmacology and Neuroscience 2020; 18 (4): 641. |
| [14] | Duan L, Gao Y, Shao X, Tian C, Fu C, Zhu G. Research on the development of theme trends and changes of knowledge structures of drug therapy studies on major depressive disorder since the 21st century: A bibliometric analysis. Frontiers in Psychiatry 2020; 11: 647. doi: 10.3389/fpsyt.2020.00647 |
| [15] | Kasteenpohja T, Marttunen M, Aalto-Setälä T, Perälä J, Saarni SI, Suvisaari J. Treatment received and treatment adequacy of depressive disorders among young adults in Finland. BMC Psychiatry 2015; 15: 47. doi: 10.1186/s12888-015-0427-8 |
| [16] | Forbes MK, Crome E, Sunderland M, Wuthrich VM. Perceived needs for mental health care and barriers to treatment across age groups. Aging & Mental Health 2017; 21 (10): 1072–8. doi: 10.1080/13607863.2016.1193121 |
| [17] | Galimberti C, Bosi MF, Volontè M, Giordano F, Dell'Osso B, Viganò CA. Duration of untreated illness and depression severity are associated with cognitive impairment in mood disorders. International Journal of Psychiatry in Clinical Practice 2020; 24 (3): 227–35. doi: 10.1080/13651501.2020.1757116 |
| [18] | Levy MJF, Boulle F, Steinbusch HW, van-den-Hove DLA, Kenis G, Lanfumey L. Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression. Psychopharmacology (Berl) 2018; 235 (8): 2195–220. doi: 10.1007/s00213-018-4950-4 |
| [19] | Greenberg ME, Xu B, Lu B, Hempstead BL. New insights in the biology of BDNF synthesis and release: Implications in CNS function. Journal of Neuroscience 2009; 29 (41): 12764–7. doi: 10.1523/JNEUROSCI.3566-09.2009 |
| [20] | Wang Z, Meng Z, Chen C. Screening of potential biomarkers in peripheral blood of patients with depression based on weighted gene co-expression network analysis and machine learning algorithms. Frontiers in Psychiatry 2022; 13: 100991. doi: 10.3389/fpsyt.2022.1009911 |
| [21] | Spellman T, Liston C. Toward circuit mechanisms of pathophysiology in depression. American Journal of Psychiatry 2020; 177 (5): 381–90. doi: 10.1176/appi.ajp.2020.20030280 |
| [22] | Li H, Song S, Wang D, Zhang D, Tan Z, Lian Z, et al. Treatment response prediction for major depressive disorder patients via multivariate pattern analysis of thalamic features. Frontiers in Computational Neuroscience 2022; 16: 837093. doi: 10.3389/fncom.2022.837093 |
| [23] | Menardi A, Momi D, Vallesi A, Barabási AL, Towlson EK, Santarnecchi E. Maximizing brain networks engagement via individualized connectome-wide target search. Brain Stimulation 2022; 15 (6): 1418–31. doi: https://doi.org/10.1016/j.brs.2022.09.011 [Online ahead of print]. |
| [24] | Khoodoruth MAS, Estudillo-Guerra MA, Pacheco-Barrios K, Nyundo A, Chapa-Koloffon G, Ouanes S. Glutamatergic system in depression and its role in neuromodulatory techniques optimization. Frontiers in Psychiatry 2022; 13: 886918. doi: 33.10.3389/fpsyt.2022.886918 |
| [25] | Lin CH, Wang SH, Lane HY. Effects of sodium benzoate, a D-amino acid oxidase inhibitor, on perceived stress and cognitive function among patients with late-life depression: A randomized, double-blind, sertraline- and placebo-controlled trial. International Journal of Neuropsychopharmacology 2022; 25 (7): 545–55. doi: 10.1093/ijnp/pyac006 |
| [26] | Perlman G, Cogo-Moreira H, Wu CY, Herrmann N, Swardfager W. Depression interacts with allostatic load to predict cognitive decline in middle age. Psychoneuroendocrinology 2022; 146: 105922. doi: 10.1016/j.psyneuen.2022.105922 |
| [27] | Soria V, Uribe J, Salvat-Pujol N, Palao D, Menchón JM, Labad J. Psiconeuroinmunología de los trastornos mentales. [Psychoneuroimmunology of mental disorders]. Revista de Psiquiatría y Salud Mental 2018; 11 (2): 115–24. doi: 10.1016/j.rpsm.2017.07.006 |
| [28] | Demchenko I, Tassone VK, Kennedy SH, Dunlop K, Bhat V. Intrinsic connectivity networks of glutamate-mediated antidepressant response: A neuroimaging review. Frontiers in Psychiatry 2022; 13: 864902. doi: 10.3389/fpsyt.2022.864902 |
| [29] | Aboul-Fotouh S, Habib M, Asaad T, Kassim SK, Ghanem MH. Behavioral effects of toll-like receptor-4 antagonist 'eritoran' in an experimental model of depression: Role of prefrontal and hippocampal neurogenesis and γ-aminobutyric acid/glutamate balance. Behavioral Pharmacology 2018; 29 (5): 413–25. doi: 10.1097/FBP.0000000000000390 |
| [30] | Gao YN, Zhang YQ, Wang H, Deng YL, Li NM. A New player in depression: MiRNAs as modulators of altered synaptic plasticity. International Journal of Molecular Sciences 2022; 23 (9): 4555. doi: 10.3390/ijms23094555 |
| [31] | Dean RL, Hurducas C, Hawton K, Spyridi S, Cowen PJ, Hollingsworth S, et al. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database of Systematic Reviews 2021; 9 (9): CD011612. doi: 10.1002/14651858 |
| [32] | Dean RL, Marquardt T, Hurducas C, Spyridi S, Barnes A, Smith R, et al. Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder. Cochrane Database of Systematic Reviews 2021; 10 (10): CD011611. doi: 10.1002/14651858.CD011611.pub3 |
| [33] | Kang MJY, Hawken E, Vazquez GH. The mechanisms behind rapid antidepressant effects of Ketamine: A systematic review with a focus on molecular neuroplasticity. Frontiers in Psychiatry 2022; 13: 860882. doi: 10.3389/fpsyt.2022.860882 |
| [34] | Fullana MN, Paz V, Artigas F, Bortolozzi A. Ketamine triggers rapid antidepressant effects by modulating synaptic plasticity in a new depressive-like mouse model based on astrocyte glutamate transporter GLT-1 knockdown in infralimbic cortex. Revista de Psiquiatría y Salud Mental 2022; 15 (2): 94–100. doi: 10.1016/j.rpsm.2021.09.002 |
| [35] | Flux MC, Lowry CA. Finding intestinal fortitude: Integrating the microbiome into a holistic view of depression mechanisms, treatment, and resilience. Neurobiology of Disease 2020; 135: 104578. doi: 10.1016/j.nbd.2019.104578 |
| [36] | Lach G, Schellekens H, Dinan TG, Cryan JF. Anxiety, depression, and the microbiome: A role for gut peptides. Neurotherapeutics 2018; 15 (1): 36–59. doi: 10.1007/s13311-017-0585-0 |
| [37] | Młynarska E, Gadzinowska J, Tokarek J, Forycka J, Szuman A, Franczyk B, et al. The role of the microbiome-brain-gut axis in the pathogenesis of depressive disorder. Nutrients 2022; 14 (9): 1921. doi: 10.3390/nu14091921 |
| [38] | Goh KK, Chang SC, Chen CH, Lu ML. Therapeutic strategies for treatment-resistant depression: State of the art and future perspectives. Current Pharmaceutical Design 2020; 26 (2): 244–52. doi: 10.2174/1381612826666200110101604 |
| [39] | Hetrick SE, McKenzie JE, Bailey AP, Sharma V, Moller CI, Badcock PB, et al. New generation antidepressants for depression in children and adolescents: A network meta-analysis. Cochrane Database of Systematic Reviews 2021; 5 (5): CD013674. doi: 10.1002/14651858.CD013674.pub2 |
| [40] | Zhou X, Teng T, Zhang Y, del-Giovane C, Furukawa TA, Weisz JR, et al. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: A systematic review and network meta-analysis. The Lancet Psychiatry 2020; 7 (7): 581–601. doi: 10.1016/S2215-0366(20)30137-1 |
| [41] | Walter HJ, Abright AR, Bukstein OG, Diamond J, Keable H, Ripperger-Suhler J, et al. Clinical practice guideline for the assessment and treatment of children and adolescents with major and persistent depressive disorders. Journal of the American Academy of Child and Adolescent Psychiatry 2022. [article in press] https://www.jaacap.org/article/S0890-8567(22)01852-4/pdf |
| [42] | Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. The Lancet 2018; 391 (10128): 1357–66. doi: 10.1016/S0140-6736(17)32802-7 |
| [43] | Yang Z, Jian L, Qiu H, Zhang C, Cheng S, Ji J, et al. Understanding complex functional wiring patterns in major depressive disorder through brain functional connectome. Translational Psychiatry 2021; 11 (1): 526. doi: 10.1038/s41398-021-01646-7 |
| [44] | Yang H, Gao S, Li J, Yu H, Xu J, Lin C, et al. Remission of symptoms is not equal to functional recovery: Psychosocial functioning impairment in major depression. Frontiers in Psychiatry 2022; 13: 915689. doi: 10.3389/fpsyt.2022.915689 |
| [45] | Yun JY, Kim YK. Graph theory approach for the structural-functional brain connectome of depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2021; 111: 110401. doi: 10.1016/j.pnpbp.2021.110401 |
| [46] | Song Y, Wang K, Wei Y, Zhu Y, Wen J, Luo Y. Graph theory analysis of the cortical functional network during sleep in patients with depression. Frontiers in Physiology 2022; 13: 858739. doi: 10.3389/fphys.2022.858739 |
| [47] | Chai X, Zhang R, Xue C, Li Z, Xiao W, Huang Q, et al. Altered atterns of the fractional amplitude of low-frequency fluctuation in drug-naive first-episode unipolar and bipolar depression. Frontiers in Psychiatry 2020; 11: 587803. doi: 10.3389/fpsyt.2020.587803 |
| [48] | Gao Y, Wang X, Xiong Z, Ren H, Liu R, Wei Y, et al. Abnormal fractional amplitude of low-frequency fluctuation as a potential imaging biomarker for first-episode major depressive disorder: A resting-state fMRI study and support vector machine analysis. Frontiers in Neurology 2021; 12: 751400. doi: 10.3389/fneur.2021.751400 |
| [49] | Chen Q, Bi Y, Zhao X, Lai Y, Yan W, Xie L, et al. Regional amplitude abnormities in the major depressive disorder: A resting-state fMRI study and support vector machine analysis. Journal of Affective Disorders 2022; 308: 1–9. doi: 10.1016/j.jad.2022.03.079 |
| [50] | Gartlehner G, Gaynes BN, Amick HR, Asher GN, Morgan LC, Coker-Schwimmer E, et al. Comparative benefits and harms of antidepressant, psychological, complementary, and exercise treatments for major depression: An evidence report for a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine 2016; 164 (5): 331–41. doi: 10.7326/M15-1813 |
| [51] | Kappelmann N, Rein M, Fietz J, Mayberg HS, Craighead WE, Dunlop BW, et al. Psychotherapy or medication for depression? Using individual symptom meta-analyses to derive a Symptom-Oriented Therapy (SOrT) metric for a personalised psychiatry. BMC Medicine 2020; 18 (1): 170. doi: 10.1186/s12916-020-01623-9 |
| [52] | Dragioti E, Solmi M, Favaro A, Fusar-Poli P, Dazzan P, Thompson T, et al. Association of antidepressant use with adverse health outcomes: A systematic umbrella review. JAMA Psychiatry 2019; 76 (12): 1241–55. doi: 10.1001/jamapsychiatry.2019.2859 Erratum in: JAMA Psychiatry 2021; 78 (5): 569. |
| [53] | Hadjipavlou G, Hernandez CA, Ogrodniczuk JS. Psychotherapy in contemporary psychiatric practice. Canadian Journal of Psychiatry 2015; 60 (6): 294–300. doi: 10.1177/070674371506000609 |
| [54] | Ijaz S, Davies P, Williams CJ, Kessler D, Lewis G, Wiles N. Psychological therapies for treatment-resistant depression in adults. Cochrane Database of Systematic Reviews 2018; 5 (5): CD010558. doi: 10.1002/14651858.CD010558.pub2 |
| [55] | Malhi GS, Bell E, Bassett D, Boyce P, Bryant R, Hopwood M, et al. The management of depression: The evidence speaks for itself. The British Journal of Psychiatry 2022; 1–3. doi: 10.1192/bjp.2022.133 |
| [56] | Lee Y, Brietzke E, Cao B, Chen Y, Linnaranta O, Mansur RB, et al. Development and implementation of guidelines for the management of depression: A systematic review. Bulletin of the World Health Organization 2020; 98 (10): 683–97H. doi: 10.2471/BLT.20.251405 |
| [57] | Gabriel FC, Stein AT, de-Melo DO, Fontes-Mota GCH, Dos-Santos IB, de-Oliveira AF, et al. Quality of clinical practice guidelines for inadequate response to first-line treatment for depression according to AGREE II checklist and comparison of recommendations: a systematic review. BMJ Open 2022; 12 (4): e051918. doi: 10.1136/bmjopen-2021-051918 |
| [58] | Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. New England Journal of Medicine 2000; 342 (20): 1462–70. doi: 10.1056/NEJM200005183422001 Correction: New England Journal of Medicine 2001; 345 (3): 232. |
| [59] | de-Maat SM, Dekker J, Schoevers RA, de-Jonghe F. Relative efficacy of psychotherapy and combined therapy in the treatment of depression: A meta-analysis. European Psychiatry 2007; 22 (1): 1–8. https://www.sciencedirect.com/science/article/abs/pii/S0924933806001866 |
| [60] | Machmutow K, Meister R, Jansen A, Kriston L, Watzke B, Härter MC, et al. Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults. Cochrane Database of Systematic Reviews 2019; 5 (5): CD012855. doi: 10.1002/14651858 |
| [61] | Hansen HV, Christensen EM, Dam H, Gluud C, Wetterslev J, Kessing LV, et al. The effects of centralised and specialised intervention in the early course of severe unipolar depressive disorder: A randomised clinical trial. PLoS One 2012; 7 (3): e32950. doi: 10.1371/journal.pone.0032950 |
| [62] | Bertolín-Guillén JM. Adicciones y salud mental: necesidad de colaboración e integración de la gestión asistencial. [Addictions and mental health: A need for collaboration and integration in healthcare management.] Revista Española de Drogodependencias 2019: 44 (2): 5–12. https://www.aesed.com/upload/files/v44n2_editorial1.pdf |
| [63] | Verduijn J, Verhoeven JE, Milaneschi Y, Schoevers RA, van Hemert AM, Beekman ATF, et al. Reconsidering the prognosis of major depressive disorder across diagnostic boundaries: Full recovery is the exception rather than the rule. BMC Medicine 2017; 15: 215. https://doi.org/10.1186/s12916-017-0972-8 |
| [64] | ten-Have M, Tuithof M, van-Dorsselaer S, de-Beurs D, de-Graaf R, Batelaan NM, et al. How chronic are depressive and anxiety disorders? 9-year general population study using narrow and broad course outcomes. Journal of Affective Disorders 2022; 317: 149–55. doi: 10.1016/j.jad.2022.08.083 |
| [65] | d'Avanzato C, Martinez J, Attiullah N, Friedman M, Toba C, Boerescu DA, et al. Anxiety symptoms among remitted depressed outpatients: Prevalence and association with quality of life and psychosocial functioning. Journal of Affective Disorders 2013; 151 (1): 401–4. doi: 10.1016/j.jad.2013.06.040 |
| [66] | Harris MG, Kazdin AE, Chiu WT, Sampson NA, Aguilar-Gaxiola S, Al-Hamzawi A, et al. Findings from World Mental Health Surveys of the perceived helpfulness of treatment for patients with major depressive disorder. JAMA Psychiatry 2020; 77 (8): 830–41. doi: 10.1001/jamapsychiatry.2020.1107 |
| [67] | Peeters N, Stappenbelt S, Burk WJ, van-Passel B, Krans J. Schema therapy with exposure and response prevention for the treatment of chronic anxiety with comorbid personality disorder. British Journal of Clinical Psychology 2021; 60 (1): 68–76. doi: 10.1111/bjc.12271 |
| [68] | Khazanov GK, Xu C, Hollon SD, DeRubeis RJ, Thase ME. Adding cognitive therapy to antidepressant medications decreases suicidal ideation. Journal of Affective Disorders 2021; 281: 183–91. doi: 10.1016/j.jad.2020.12.032 |
| [69] | Bertolín-Guillén JM. Psychotherapies in current clinical psychology and psychiatry in Spain. Revista de Psiquiatría y Salud Mental 2020; S1888-9891(20)30023-9. [Online ahead of print] doi: 10.1016/j.rpsm.2020.01.004 |
| [70] | Cox GR, Callahan P, Churchill R, Hunot V, Merry SN, Parker AG, et al. Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents. Cochrane Database of Systematic Reviews 2012; 11: CD008324. doi: 10.1002/14651858.CD008324.pub2 Update in: Cochrane Database of Systematic Reviews 2014; 11: CD008324. |
| [71] | Dunlop BW, LoParo D, Kinkead B, Mletzko-Crowe T, Cole SP, Nemeroff CB, et al. Benefits of sequentially adding cognitive-behavioral therapy or antidepressant medication for adults with nonremitting depression. American Journal of Psychiatry 2019; 176 (4): 275–86. doi: 10.1176/appi.ajp.2018.18091075 |
| [72] | Bockting CLH, Klein NS, Elgersma HJ, van-Rijsbergen GD, Slofstra C, Ormel J, et al. Effectiveness of preventive cognitive therapy while tapering antidepressants versus maintenance antidepressant treatment versus their combination in prevention of depressive relapse or recurrence (DRD study): A three-group, multicentre, randomised controlled trial. The Lancet Psychiatry 2018; 5 (5): 401–10. doi: 10.1016/S2215-0366(18)30100-7 |
| [73] | Bertolín-Guillén JM. Delitos en el ámbito de la salud mental. [Crimes in the field of mental health.] Gaceta Internacional de Ciencias Forenses 2022; [12] (43): 20–8. https://www.uv.es/gicf/3R1_Bertolin_GICF_43.pdf |
| [74] | Unidad de Asesoramiento Científico-Técnico. Guía de práctica clínica sobre el manejo de la depresión mayor en la infancia y adolescencia. Actualización. [Clinical practice guideline on the management of major depression in childhood and adolescence. Update.] Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad; 2018. |
| [75] | American Psychological Association. APA clinical practice guideline for the treatment of depression across three age cohorts. APA: Washington, DC; 2019. https://www.apa.org/depression-guideline/guideline.pdf |
APA Style
José Manuel Bertolín-Guillén. (2023). Psychiatric Psychobiological Treatment Versus Exclusive Psychological Treatment in Depressive Disorders. American Journal of Psychiatry and Neuroscience, 11(1), 13-21. https://doi.org/10.11648/j.ajpn.20231101.12
ACS Style
José Manuel Bertolín-Guillén. Psychiatric Psychobiological Treatment Versus Exclusive Psychological Treatment in Depressive Disorders. Am. J. Psychiatry Neurosci. 2023, 11(1), 13-21. doi: 10.11648/j.ajpn.20231101.12
AMA Style
José Manuel Bertolín-Guillén. Psychiatric Psychobiological Treatment Versus Exclusive Psychological Treatment in Depressive Disorders. Am J Psychiatry Neurosci. 2023;11(1):13-21. doi: 10.11648/j.ajpn.20231101.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajpn.20231101.12,
author = {José Manuel Bertolín-Guillén},
title = {Psychiatric Psychobiological Treatment Versus Exclusive Psychological Treatment in Depressive Disorders},
journal = {American Journal of Psychiatry and Neuroscience},
volume = {11},
number = {1},
pages = {13-21},
doi = {10.11648/j.ajpn.20231101.12},
url = {https://doi.org/10.11648/j.ajpn.20231101.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajpn.20231101.12},
abstract = {Introduction: Scientific information on the antidepressant effectiveness of the varied usual therapeutic interventions is considerable but of poor quality. Objective: To analyse the scientifically well qualified international contributions on the effectiveness of habitual psychobiological psychiatric interventions in depressive disorders. Method: N= 6 structured bibliographic systems have been reviewed in a non-systematic, narrative and synthetic way and N= 75 significant contributions have been selected. Results and discussion: Patients with severe depression are more likely to receive any type of medical attention, but less likely to receive adequate attention. The use of both drugs and psychotherapy is the habitual mixed combined intervention during any ordinary psychiatric treatment. We will call it psychobiological or psychopharmacological intervention. The exclusive psychological intervention without using any medically prescribed drugs, is likely to be less cost/effective. The matter is not only to prioritise but also to adequately combine psychiatric interventions and added psychological interventions when convenient. The intervention on the neurophysiological pathways related with glutamate, the GABAergic, opioidergic, and inflammatory systems as well as on connectome and microbiome are being promoted for future drug antidepressant therapy with encouraging results. Conclusion: The mixed psychiatric option using drugs and psychotherapy, either regulated or not, by the intervening psychiatrist himself or herself is probably the main therapeutic choice for the correctly diagnosed depressive disorders. The psychotherapeutics intervention excluding the psychobiological psychiatric intervention in correctly diagnosed depressions will be insufficient in general. The professional psychological intervention may obviously complement the mixed psychiatric intervention, but can not replace it.},
year = {2023}
}
TY - JOUR T1 - Psychiatric Psychobiological Treatment Versus Exclusive Psychological Treatment in Depressive Disorders AU - José Manuel Bertolín-Guillén Y1 - 2023/02/16 PY - 2023 N1 - https://doi.org/10.11648/j.ajpn.20231101.12 DO - 10.11648/j.ajpn.20231101.12 T2 - American Journal of Psychiatry and Neuroscience JF - American Journal of Psychiatry and Neuroscience JO - American Journal of Psychiatry and Neuroscience SP - 13 EP - 21 PB - Science Publishing Group SN - 2330-426X UR - https://doi.org/10.11648/j.ajpn.20231101.12 AB - Introduction: Scientific information on the antidepressant effectiveness of the varied usual therapeutic interventions is considerable but of poor quality. Objective: To analyse the scientifically well qualified international contributions on the effectiveness of habitual psychobiological psychiatric interventions in depressive disorders. Method: N= 6 structured bibliographic systems have been reviewed in a non-systematic, narrative and synthetic way and N= 75 significant contributions have been selected. Results and discussion: Patients with severe depression are more likely to receive any type of medical attention, but less likely to receive adequate attention. The use of both drugs and psychotherapy is the habitual mixed combined intervention during any ordinary psychiatric treatment. We will call it psychobiological or psychopharmacological intervention. The exclusive psychological intervention without using any medically prescribed drugs, is likely to be less cost/effective. The matter is not only to prioritise but also to adequately combine psychiatric interventions and added psychological interventions when convenient. The intervention on the neurophysiological pathways related with glutamate, the GABAergic, opioidergic, and inflammatory systems as well as on connectome and microbiome are being promoted for future drug antidepressant therapy with encouraging results. Conclusion: The mixed psychiatric option using drugs and psychotherapy, either regulated or not, by the intervening psychiatrist himself or herself is probably the main therapeutic choice for the correctly diagnosed depressive disorders. The psychotherapeutics intervention excluding the psychobiological psychiatric intervention in correctly diagnosed depressions will be insufficient in general. The professional psychological intervention may obviously complement the mixed psychiatric intervention, but can not replace it. VL - 11 IS - 1 ER -
Email: